Key Takeaway: The FDA has approved LEQEMBI IQLIK (lecanemab-irmb) as a subcutaneous injection for early Alzheimer's disease. This innovative treatment allows for at-home dosing, making it more accessible for patients. The U.S. launch is scheduled for late August 2026, representing a significant advancement in Alzheimer's care.
Price reaction · baseline $209.03 (2026-07-13 close) · hit after-hours · 3 other BIIB headline(s) in the window, move may be shared
day 0 close · peak
-8.2%
day 1
-5.6%
day 3
-1.5%
Market Sentiment Analysis
POSITIVE FACTORS
First anti-amyloid treatment for Alzheimer's disease.
FDA approval marks a significant milestone for Alzheimer's treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis
Full Press Release Details
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026 TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai
Frequently Asked Questions
What is LEQEMBI IQLIK?
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment for Alzheimer's disease.
When will LEQEMBI IQLIK be launched in the U.S.?
The U.S. launch of LEQEMBI IQLIK is planned for late August 2026.
What are the benefits of LEQEMBI IQLIK?
It offers at-home dosing for both initiation and maintenance of treatment.